Latest News

Latest News

Lilly vs Novo in 2026: How the Obesity Market Has Shifted

Lilly vs Novo in 2026: How the Obesity Market Has Shifted

Lilly vs Novo is the rivalry that defines obesity medicine, and 2026 has redrawn the balance between the two companies. Third-quarter results published on 29 October and 4 November show Eli Lilly growing at a scale few drugmakers have reached. Novo Nordisk, meanwhile,...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Bispecific T-Cell Engagers in Refractory Autoimmune Disease

Bispecific T-Cell Engagers in Refractory Autoimmune Disease

Bispecific T-cell engagers, originally developed to redirect immune responses against cancer, are being investigated as potential therapeutic candidates for treatment-refractory autoimmune connective tissue diseases. A 2026 study published in Nature Medicine reported...

read more
Medicine Does Not Run on Blood Alone

Medicine Does Not Run on Blood Alone

Prevention-first urine diagnostics will depend not only on how accurately we can measure disease, but on how often and how easily people can be tested. Blood is medicine's default diagnostic medium for good reasons. It circulates through the whole body, carries a...

read more
Bispecific T-Cell Engagers in Refractory Autoimmune Disease

Bispecific T-Cell Engagers in Refractory Autoimmune Disease

Bispecific T-cell engagers, originally developed to redirect immune responses against cancer, are being investigated as potential therapeutic candidates for treatment-refractory autoimmune connective tissue diseases. A 2026 study published in Nature Medicine reported...

read more
Medicine Does Not Run on Blood Alone

Medicine Does Not Run on Blood Alone

Prevention-first urine diagnostics will depend not only on how accurately we can measure disease, but on how often and how easily people can be tested. Blood is medicine's default diagnostic medium for good reasons. It circulates through the whole body, carries a...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

A Regulatory Playbook for SaMD and Digital Health

A Regulatory Playbook for SaMD and Digital Health

Six decisions that shape FDA readiness for software as a medical device and connected digital health products A software team can build a compelling product and still reach the submission stage with a fundamental problem: the evidence supports a narrower claim than...

read more
Weekly News Roundup | 12 October 2026

Weekly News Roundup | 12 October 2026

Life science news 12 October 2026: three deals, three US approvals and two UK regulatory updates. Shionogi agreed to buy IntraBio for $2bn. Viatris offered $1.65bn for Pacira BioSciences. The FDA approved Tecentriq for Stage III dMMR colon cancer. Shionogi will...

read more
Will the NHS Offer Atezolizumab for dMMR Colon Cancer?

Will the NHS Offer Atezolizumab for dMMR Colon Cancer?

Not yet, and no UK date has been set. The US FDA approved atezolizumab (Tecentriq) on 8 October 2026 for stage III dMMR colon cancer. NICE has an appraisal in scoping, with no publication date. The emc product summary for Tecentriq 1,200 mg lists six indications....

read more
Viatris Pacira Acquisition: What the $1.65bn Deal Buys

Viatris Pacira Acquisition: What the $1.65bn Deal Buys

The Viatris Pacira acquisition buys two US pain products, Exparel and Zilretta, for $36.50 per share in cash. That values Pacira BioSciences at $1.65 billion. Viatris announced the agreement on 8 October 2026. It expects the deal to close by the end of 2026. Closing...

read more
GLP-1 Therapy: More Than Numbers on a Scale

GLP-1 Therapy: More Than Numbers on a Scale

The advent of GLP-1 medications has radically changed the conversation about the treatment of obesity. Effective treatments such as semaglutide and tirzepatide have grown in popularity and use, with more agents in the pharmaceutical pipeline. However, the treatment of...

read more
Clinical Trial Results | 9 October 2026

Clinical Trial Results | 9 October 2026

The clinical trial results 9 October 2026 span haematological oncology, rare skeletal disease, metabolic medicine, coeliac disease and autoimmunity. The FDA expanded Eli Lilly’s Jaypirca into previously untreated chronic lymphocytic leukaemia. BridgeBio Pharma’s oral...

read more
Petrelintide in Type 2 Diabetes: How Does It Compare?

Petrelintide in Type 2 Diabetes: How Does It Compare?

Petrelintide in type 2 diabetes cannot yet be ranked against tirzepatide or semaglutide, because the trial designs differ. Zealand Pharma, which develops the drug with Roche, reported Phase 2b ZUPREME-2 topline data on 7 October 2026. Mean weight loss reached up to...

read more

Further News

Weight Is Not Composition: What Surgeons See After GLP-1 Weight Loss

The GLP-1 era has given clinicians something they have wanted for decades: medications that produce weight loss approaching what was once possible only with surgery. Semaglutide and tirzepatide routinely deliver reductions of 15% to 20% of body weight in trials, and...

Ferring Gameto Acquisition: What Does Ferring Get From the Deal?

The Ferring Gameto acquisition would give Ferring Pharmaceuticals control of Fertilo, Gameto’s lead investigational fertility programme. Fertilo is derived from induced pluripotent stem cells and is designed to mature eggs outside the body. Ferring and Gameto...

What the Next Generation of GLP-1s Means for Pharmacists and Patients

GLP-1 receptor agonists (GLP-1 RAs) have reshaped the treatment of type 2 diabetes and obesity. But the next phase of GLP-1 therapy, and of incretin-based treatment more broadly, is likely to have implications that extend well beyond the approval of another...

Del-Desiran Next Steps: Will Novartis Continue After HARBOR?

Novartis has not yet said whether it will keep developing del-desiran, its drug for myotonic dystrophy type 1 (DM1). The del-desiran next steps depend on the full HARBOR dataset and on talks with regulators. On 27 October 2026, Novartis reported a USD 1.9 billion...

Interoperability Begins Where Data Exchange Ends

Standards and APIs can move information. True healthcare interoperability requires the governance, trust and workflow design that make the information usable. Healthcare has spent years treating interoperability as a problem of moving data. National exchange has...

Psychobiotics and Depression: Exploring the Gut–Brain Connection

Depression care continues to evolve as researchers explore why people respond differently to treatment. One area drawing attention is the relationship between the gut microbiome and the brain. Could psychobiotics, which target this connection, offer additional support...

GLP-1s in Adolescents: What the Paediatric Obesity Evidence Shows

The case for GLP-1s in adolescents with obesity now rests on several randomised trials and two marketing authorisations. Real-world data are growing too. That evidence shows substantial reductions in body mass index over 56 to 68 weeks. It says much less about years...

Eppendorf and BioLabs Expand Collaboration to Munich

The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies. It builds on existing partnerships at BioLabs sites across the US, Germany and France. HAMBURG and MUNICH, Germany, 21 October 2026...

Divarasib Approval: When Could Roche’s KRAS Inhibitor Reach Patients?

Divarasib approval cannot yet be dated. Roche has not announced a filing after the Krascendo 1 phase 3 results at ESMO 2026.

    Beyond Screen Time: How Digital Habits Shape Attention and Memory

    As digital platforms make information increasingly accessible, the challenge is no longer simply how much we consume, but how our digital habits affect the way we process, retain, and use it. Scrolling through social media can expose us to hundreds of pieces of...

    ZW209 Licensing Deal: What Does Roche Get From Zymeworks?

    Roche will receive exclusive global rights to ZW209 for $55 million upfront, a $40 million Phase 1b milestone, up to $718 million in further milestones and royalties, pending HSR clearance.

      What FDA’s “Healthy” Rule and Front-of-Pack Labelling Mean for Food Makers

      Two changes are reshaping what goes on the front of a US food package. The first, a new definition of the "healthy" nutrient content claim, is already law, with enforcement starting on 25 February 2028 [1]. The second, mandatory front-of-pack labelling in the form of...

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.